Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Multiple myeloma is the second most common adult haematological malignancy. One of the major clinical features is the development of a unique osteolytic bone disease, characterised by progressive and devastating bone destruction, bone pain, pathological fractures and hypercalcaemia. Bisphosphonates, inhibitors of osteoclastic bone resorption, are the standard therapy for myeloma-induced bone disease. However, as our understanding of the molecular mechanisms involved in the development of myeloma bone disease increases, new molecular targets have been identified for the treatment of this devastating bone disease.

Original publication

DOI

10.1517/14656566.6.16.2781

Type

Journal article

Journal

Expert Opin Pharmacother

Publication Date

12/2005

Volume

6

Pages

2781 - 2791

Keywords

Animals, Bone Neoplasms, Disease Management, Drug Delivery Systems, Drugs, Investigational, Humans, Multiple Myeloma